A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC) Meeting Abstract

  

Authors:	Forsyth, P. A. J.; Gandhi, S.; Wilcox, J.; Law, V.; Mo, Q.; Chen, Z.; Ahmed, K. A.; Piteo, C.; Evernden, B.; Pina, Y.; Boire, A. A.; Kalinski, P.; Czerniecki, B. J.
Abstract Title:	A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC)
Meeting Title:	2024 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	16 Suppl.
Meeting Dates:	2024 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-06-01
Language:	English
ACCESSION:	WOS:001275557406078
PROVIDER:	wos
DOI:	10.1200/JCO.2024.42.16_suppl.TPS2090
Notes:	Meeting Abstract: TPS2090 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218764